These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 30043330)
41. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell]. Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693 [TBL] [Abstract][Full Text] [Related]
42. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization. Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786 [TBL] [Abstract][Full Text] [Related]
43. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. Wagstaff AJ Drugs; 2009; 69(3):319-26. PubMed ID: 19275275 [TBL] [Abstract][Full Text] [Related]
44. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Keating GM Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545 [TBL] [Abstract][Full Text] [Related]
45. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison. Valtola J; Varmavuo V; Ropponen A; Nihtinen A; Partanen A; Vasala K; Lehtonen P; Penttilä K; Pyörälä M; Kuittinen T; Silvennoinen R; Nousiainen T; Pelkonen J; Mäntymaa P; Jantunen E Transfusion; 2015 Oct; 55(10):2358-68. PubMed ID: 26018461 [TBL] [Abstract][Full Text] [Related]
46. Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor. Shi PA; Miller LK; Isola LM Transfusion; 2014 May; 54(5):1263-8. PubMed ID: 24128272 [TBL] [Abstract][Full Text] [Related]
47. Plerixafor: what we still have to learn. Lanza F; Gardellini A; Laszlo D; Martino M Expert Opin Biol Ther; 2015 Feb; 15(2):143-7. PubMed ID: 25315706 [TBL] [Abstract][Full Text] [Related]
48. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180 [TBL] [Abstract][Full Text] [Related]
49. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194 [TBL] [Abstract][Full Text] [Related]
50. Etoposide + Granulocyte Colony-Stimulating Factor and Optional Plerixafor in Patients Who Failed Chemomobilization with or without Plerixafor. Zucenka A; Peceliunas V; Maciutaite E; Chaleckaite J; Jakimaviciute R; Griskevicius L Biol Blood Marrow Transplant; 2019 Jul; 25(7):1304-1311. PubMed ID: 30871977 [TBL] [Abstract][Full Text] [Related]
55. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. DiPersio JF; Stadtmauer EA; Nademanee A; Micallef IN; Stiff PJ; Kaufman JL; Maziarz RT; Hosing C; Früehauf S; Horwitz M; Cooper D; Bridger G; Calandra G; Blood; 2009 Jun; 113(23):5720-6. PubMed ID: 19363221 [TBL] [Abstract][Full Text] [Related]
56. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Dhakal B; Veltri LW; Fenske TS; Eastwood D; Craig MD; Cumpston A; Shillingburg A; Esselman J; Watkins K; Pasquini MC; D'Souza A; Hari P; Kanate AS; Hamadani M Biol Blood Marrow Transplant; 2016 Oct; 22(10):1773-1780. PubMed ID: 27345140 [TBL] [Abstract][Full Text] [Related]
57. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382 [TBL] [Abstract][Full Text] [Related]
58. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198 [TBL] [Abstract][Full Text] [Related]
59. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442 [TBL] [Abstract][Full Text] [Related]
60. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]